Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leuk...

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leukemia  Nature

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM - Hematology A...

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM  Hematology Advisor

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma - Targeted Oncology

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma  Targeted Oncology

Continuous Low-Dose Lenalidomide Delivery for Hematologic Malignancies: Preclinical to Phase 2 In...

Continuous Low-Dose Lenalidomide Delivery for Hematologic Malignancies: Preclinical to Phase 2 Insights  Labroots

Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre...

Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group  BMC Medicine

Epcoritamab Plus Rituximab and Lenalidomide Hits Both Primary End Points in R/R Follicular Lympho...

Epcoritamab Plus Rituximab and Lenalidomide Hits Both Primary End Points in R/R Follicular Lymphoma  OncLive

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma -...

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma  Pharmacy Times

Safety and Efficacy of Direct Oral Anticoagulants as Thromboprophylaxis in Patients With Multiple...

Safety and Efficacy of Direct Oral Anticoagulants as Thromboprophylaxis in Patients With Multiple Myeloma Receiving a Lenalidomide-Based Induction Regimen  Journal of Hematology Oncology Pharmacy

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: A...

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses  Nature

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma - OncLive

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma  OncLive

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple ...

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma  Pharmacy Times

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with h...

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial  Nature

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Dia...

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed Myeloma  OncLive

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA lon...

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes | Leukemia  Nature

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma...

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma  OncLive

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of eld...

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma  Nature

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, New...

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma  OncLive

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor ...

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial  Nature

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma - OncLive

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma  OncLive

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and...

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation  Nature

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transpla...

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial  Nature

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multipl...

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma  Pharmacy Times

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myelom...

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myeloma  OncLive

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma - OncLive

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma  OncLive

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractor...

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma  The ASCO Post

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgro...

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study | Leukemia  Nature

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly D...

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma  OncLive

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma - OncLive

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma  OncLive

IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myel...

IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myeloma  Pharmacy Times

Lenalidomide-induced type II Kounis syndrome: a case report - Frontiers

Lenalidomide-induced type II Kounis syndrome: a case report  Frontiers

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate i...

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate in Newly Diagnosed MM  ASCO Daily News

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoc...

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review  Frontiers

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths - AJMC

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths  AJMC

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma - OncLive

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma  OncLive

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory ...

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma  OncLive

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma  OncLive

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma - Targeted Oncology

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma  Targeted Oncology

Belantamab Mafodotin Triplet Improved Survival, Responses in Patients Refractory to Lenalidomide ...

Belantamab Mafodotin Triplet Improved Survival, Responses in Patients Refractory to Lenalidomide  Pharmacy Times

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lympho...

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lymphoma  OncLive

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma  OncLive

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies - CancerNetwork

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies  CancerNetwork

Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety - Pharm...

Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety  Pharmacy Times

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma - The ASCO Post

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma  The ASCO Post

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamet...

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GE  The Lancet

Elranatamab/Daratumumab/Lenalidomide Delivers Strong Response Rates in Transplant-Ineligible Myel...

Elranatamab/Daratumumab/Lenalidomide Delivers Strong Response Rates in Transplant-Ineligible Myeloma  OncLive

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL - OncLive

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL  OncLive

The lenalidomide derivative loaded and quercetin modified MIL-100 based novel drug delivery syste...

The lenalidomide derivative loaded and quercetin modified MIL-100 based novel drug delivery system for breast cancer treatment  ScienceDirect.com

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rit...

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL  Pharmacy Times

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecu...

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes  Nature

FDA Approves Brentuximab Vedotin Plus Lenalidomide/Rituximab for R/R LBCL - OncLive

FDA Approves Brentuximab Vedotin Plus Lenalidomide/Rituximab for R/R LBCL  OncLive

Real-World Data Support Rituximab Plus Lenalidomide in NHL - AJMC

Real-World Data Support Rituximab Plus Lenalidomide in NHL  AJMC

Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response - On...

Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response  OncLive

Lenalidomide-Associated Liver Injury With Features of Vanishing Bile Duct Syndrome in Multiple My...

Lenalidomide-Associated Liver Injury With Features of Vanishing Bile Duct Syndrome in Multiple Myeloma  Cureus

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Fo...

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Follicular Lymphoma  OncLive

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Fo...

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT  OncLive

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL - CancerNetwork

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL  CancerNetwork

ASCO 2025: Adding Elranatamab to Daratumumab, Lenalidomide Induces Durable Responses in Newly Dia...

ASCO 2025: Adding Elranatamab to Daratumumab, Lenalidomide Induces Durable Responses in Newly Diagnosed Multiple Myeloma  Pharmacy Times

Supporting Treatment Decision-Making for Lenalidomide-Refractory Multiple Myeloma Patients Post-D...

Supporting Treatment Decision-Making for Lenalidomide-Refractory Multiple Myeloma Patients Post-DRd in Italy: A Multi-Criteria Decision Framework  European Medical Journal

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicul...

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma  OncLive

Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments - CancerNetwork

Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments  CancerNetwork

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide - Business Wire

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide  Business Wire

Dr Lin on Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma - OncLive

Dr Lin on Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma  OncLive

Cilta-Cel Significantly Boosts MRD Negativity Rates in Lenalidomide-Refractory Myeloma - OncLive

Cilta-Cel Significantly Boosts MRD Negativity Rates in Lenalidomide-Refractory Myeloma  OncLive

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL - OncLive

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL  OncLive

FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicula...

FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma  Managed Healthcare Executive

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q)...

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS  OncLive

How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL? - Lymphom...

How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?  Lymphoma Hub

Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular ...

Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular Lymphoma  Pharmacy Times

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphom...

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma  OncLive

Cilta-Cel Significantly Prolongs OS Vs SOC in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Significantly Prolongs OS Vs SOC in Lenalidomide-Refractory Multiple Myeloma  OncLive

Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma - National Cancer Institute (.gov)

Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma  National Cancer Institute (.gov)

Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma -...

Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma  OncLive

Incyte’s realMIND Study: A Closer Look at Tafasitamab and Lenalidomide for DLBCL - TipRanks

Incyte’s realMIND Study: A Closer Look at Tafasitamab and Lenalidomide for DLBCL  TipRanks

Future Directions After AURIGA: Daratumumab and Lenalidomide in Myeloma - Targeted Oncology

Future Directions After AURIGA: Daratumumab and Lenalidomide in Myeloma  Targeted Oncology

Ibrutinib/Lenalidomide/Rituximab Yields Long-Term Efficacy in R/R MCL - OncLive

Ibrutinib/Lenalidomide/Rituximab Yields Long-Term Efficacy in R/R MCL  OncLive

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR...

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment  Yahoo Finance

“Icing and the Cherry on Top”: Cilta-Cel Improves Quality of Life in Multiple Myeloma - Oncology ...

“Icing and the Cherry on Top”: Cilta-Cel Improves Quality of Life in Multiple Myeloma  Oncology News Central

Addition of Brentuximab Vedotin to Lenalidomide Rituximab in Relapsed or Refractory DLBCL - The A...

Addition of Brentuximab Vedotin to Lenalidomide Rituximab in Relapsed or Refractory DLBCL  The ASCO Post

(PDF) Advantageous use of lenalidomide in multiple myeloma: Discussion of three case studies - re...

(PDF) Advantageous use of lenalidomide in multiple myeloma: Discussion of three case studies  researchgate.net

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma -...

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma  OncLive

Lupin gets US FDA nod for generic drug Lenalidomide in multiple potencies - Business Standard

Lupin gets US FDA nod for generic drug Lenalidomide in multiple potencies  Business Standard

Brentuximab Vedotin Plus Lenalidomide and Rituximab Receives FDA Approval for Adults With LBCL - ...

Brentuximab Vedotin Plus Lenalidomide and Rituximab Receives FDA Approval for Adults With LBCL  Pharmacy Times

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly di...

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease | Scientific Reports  Nature

Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Admini...

Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Administration for adult patients with R/R DLBCL  Lymphoma Hub

Amneal Launches Mesalamine for Ulcerative Colitis, Receives Lenalidomide FDA Approval - HCPLive

Amneal Launches Mesalamine for Ulcerative Colitis, Receives Lenalidomide FDA Approval  HCPLive

Lenalidomide Drug Market to Reach USD 22.04 Bn by 2032 with A Growth Rate of 6.6% – Report by Coh...

Lenalidomide Drug Market to Reach USD 22.04 Bn by 2032 with A Growth Rate of 6.6% – Report by Coherent Market Insights  BioSpace

Lupin receives USFDA approval for Lenalidomide Capsules - Business Standard

Lupin receives USFDA approval for Lenalidomide Capsules  Business Standard

Dr Amengual on the Efficacy of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma - ...

Dr Amengual on the Efficacy of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma  OncLive

Dr Sekeres on Luspatercept Plus Lenalidomide in Non–5q Deletion MDS - OncLive

Dr Sekeres on Luspatercept Plus Lenalidomide in Non–5q Deletion MDS  OncLive

Ide-Cel Boosts Response in Myeloma With - OncLive

Ide-Cel Boosts Response in Myeloma With  OncLive

Rahul Banerjee: Safety run-in for Teclistamab and Lenalidomide maintenance after ASCT - Oncodaily

Rahul Banerjee: Safety run-in for Teclistamab and Lenalidomide maintenance after ASCT  Oncodaily

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety...

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database | Blood Cancer Journal  Nature

Samer Al Hadidi: Discontinuation of Lenalidomide Maintenance after ASCT in MM - Oncodaily

Samer Al Hadidi: Discontinuation of Lenalidomide Maintenance after ASCT in MM  Oncodaily

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer...

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer Journal  Nature

New breakthrough combats lenalidomide resistance in multiple myeloma - NUS - National University ...

New breakthrough combats lenalidomide resistance in multiple myeloma  NUS - National University of Singapore

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells - Science ...

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells  Science | AAAS

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multip...

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry  Nature

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelod...

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial  Nature

Dr Poh on the Preliminary Efficacy of Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicu...

Dr Poh on the Preliminary Efficacy of Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma  OncLive

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - The New England J...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma  The New England Journal of Medicine